TMO · Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Raymond James Institutional Investors Conference on Tuesday, March 3, 2026, at 9:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com , with a replay accessible shortly after the presentation concludes. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.783% of their principal amount; $1.3 billion aggregate principal amount of its 4.902% senior notes due 2036 (the “2036 notes”) at the issue price of 100.000% of their principal amount; and $750 million aggregate principal amount of its 5.546% senior notes due 2046 (the “2046 notes” and, together with the 2031 notes, the 2033 notes and the 2036 notes, the “notes”) at the issue price of 100.000% of their principal amount. The Offering is expected to close on or about February 12, 2026, subject to the satisfaction of customary

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earnings per share (EPS) grew 7% to $17.74. Full year adjusted EPS grew 5% to $22.87. Delivered another year of excellent operational performance and share gain reflecting our active management of the company, the strength of our proven growth strategy and the power of our PPI Business System. Advanced our proven growth strategy by launching a range of high-impact, innovative new products in 2025. Highlights include the Thermo Scientific™ Orbitrap™ Astral™ Zoom mass spectrometer , Thermo Scientific™ Krios™ 5 Cryo-TEM

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence (AI) platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories. The companies are working together to evolve the digital foundation that powers scientific instruments, laboratory infrastructure and data - connecting them to powerful AI solutions, helping scientists reduce manual steps and accelerate scientific advancement. Accelerating smarter, connected scientific workflows and laboratories In most laboratories today, scientists still perform many tasks manually—from designing experiments and setting up instrumentation to preparing samples, running instruments, and interpreting results. The collaboration between Thermo Fisher and NVIDIA will meaningfully contribute to

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET). A live webcast of the presentation will be available in the Investors section of our website, www.thermofisher.com , with a replay accessible shortly after the presentation concludes. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an